Riot Platforms (RIOT) 2026 stock analysis: Bitcoin mining economics, hashrate and power-cost structure, post-halving profitability, the Texas ERCOT power market and demand response, the Corsicana and Kosciusko AI/HPC data-center pivot, extreme Bitcoin-price sensitivity, share dilution, and the no-dividend model for global investors.
Hims & Hers Health (HIMS) 2026 stock analysis: the direct-to-consumer telehealth subscription model, the GLP-1 weight-loss compounding controversy and FDA regulation, category expansion across hair loss, sexual health and mental health, subscriber growth and margins, competition from Novo and Lilly, and its no-dividend high-volatility profile.
Snowflake (SNOW) 2026 stock analysis: the cloud data warehouse and lakehouse platform, its consumption-based revenue model, product revenue and net revenue retention (NRR), Cortex AI and native data apps, head-to-head competition with Databricks, plus the high-valuation and stock-based-compensation dilution risks investors must weigh.
Okta (OKTA) 2026 stock analysis: workforce and customer identity (Auth0), zero-trust IAM leadership, recovery from past security breaches, slowing growth vs. improving margins and free cash flow, competition from Microsoft Entra, Ping Identity, and SailPoint, and its no-dividend capital-allocation model.
CrowdStrike (CRWD) 2026 stock analysis: the cloud-native Falcon platform's single-agent moat across endpoint (EDR), cloud, identity, and next-gen SIEM, ARR and net revenue retention (NRR), the aftermath of the 2024 global IT outage and trust recovery, a rich valuation, and competition from Microsoft, Palo Alto Networks, and SentinelOne.
Prestige Biopharma (KOSPI 950210) 2026 stock analysis: the Tuznue trastuzumab biosimilar commercialization path and the PBP1510 (ulenistamab) pancreatic-cancer antibody's clinical and regulatory milestones, dilution risk from ongoing losses and financing, the quirks of a Singapore-domiciled foreign company listed on KOSPI, and why this is a high-risk, pipeline-driven biotech.
Kolmar BNH (KOSDAQ 200130) 2026 stock analysis: the HemoHIM proprietary ingredient, single-channel dependence on Atomy, its position inside the Korea Kolmar group as a health-functional-food ODM, export and channel diversification, and the domestic competition and channel-concentration risks that shape the investment case.
Aekyung Industrial (KOSPI: 018250) 2026 stock analysis for global investors: the AGE 20's cosmetics franchise reducing its China export dependence and rebranding, the Kerasys, 2080, and Trio household-goods cash cow, domestic consumption, raw-material and currency exposure, LINE Friends and IP collaborations, the beauty-segment rebound scenario, and Aekyung Group risk.
Cosmecca Korea (KOSDAQ: 241710) 2026 stock analysis: the cosmetics ODM/OEM manufacturing engine behind the K-beauty and indie-brand export boom, the strategic value of US subsidiary Englewood Lab and its onshore American production, the split US-China-Korea manufacturing base, customer diversification, and the input-cost, FX, and tariff variables that drive margins — analyzed qualitatively for global investors.
Grand Korea Leisure (KOSPI: 114090) 2026 stock analysis: the Seven Luck foreigner-only casino business model, Korea Tourism Organization parent (state-enterprise character), China and Japan VIP and mass tourist recovery leverage, dividend appeal, and the labor-cost, regulation, and drop-volume risks that drive earnings volatility.
Lotte Tour Development (KRX 032350) Stock Outlook 2026 covering the Jeju Dream Tower integrated resort, its foreigner-only casino drop and hold, China and Japan tourism recovery, hotel and travel operations, heavy debt and interest expense, the swing-to-profit turnaround thesis, Paradise and GKL peer comparison, and what global investors should watch.
Devsisters (194480, KOSDAQ) 2026 stock analysis for global investors: a Korean IP game maker built on the Cookie Run franchise. Cookie Run: Kingdom and OvenBreak, single-IP concentration risk, global expansion across Japan, the US and China, the new-title pipeline, hit-driven earnings volatility, and the IP-diversification thesis compared with Korean peers.
Nexon Games (KOSDAQ: 225570) 2026 stock analysis: the global Blue Archive subculture fanbase, The First Descendant console/PC push into Western markets, the Nexon parent-company umbrella, hit-driven development risk, live-service economics, game-stock valuation, and what it means for a global investor holding a Korea-listed developer.
Haesung DS (KOSPI: 195870) 2026 stock analysis for global investors: a Roll-to-Roll automotive semiconductor leadframe moat, memory- and server-oriented package (BGA) substrate growth, copper and raw-material cost pass-through, KRW/USD currency risk, the semiconductor cycle, customer-concentration exposure, and dividend appeal, all framed qualitatively.
Daeduck Electronics (KOSPI 353200) stock outlook for 2026, analyzing its pivot from low-margin PCBs to high-value FC-BGA semiconductor package substrates, AI, server and telecom demand, Samsung and other customer exposure, the memory-chip cycle, heavy capex, and competition from Japanese and Greater China rivals, plus KRW currency risk for global investors.
A 2026 guide to U.S. cyber liability insurance for ransomware for small and mid-sized businesses: what first-party coverage (ransom, business interruption, forensics, notification) and third-party coverage (liability, regulatory) actually pay for, what drives premiums, the security controls underwriters now require (MFA, EDR, immutable backups), war and nation-state exclusions, ransom payment and OFAC sanctions issues, and how SMBs should choose their limits.
How medical malpractice settlement amounts are actually determined in the U.S. as of 2026: the four elements of a malpractice claim (duty, breach of the standard of care, causation, damages), how economic, non-economic, and punitive damages are calculated, state non-economic damage caps, the statute of limitations and discovery rule, expert witnesses and certificates of merit, contingency fees, and why these cases are so hard to win — written for U.S. readers and patients.
How mesothelioma (asbestos cancer) settlements and average payouts are determined in 2026: the difference between asbestos trust funds and lawsuit litigation, typical settlement and verdict ranges, the factors that drive payout (exposure history, diagnosis stage, jurisdiction), the discovery-rule statute of limitations, VA benefits for veterans exposed during service, and how to choose a contingency-fee mesothelioma attorney — explained for U.S. readers.
How U.S. wrongful death settlements are calculated in 2026: who can file (eligible beneficiaries), economic damages (lost income and support, funeral costs) versus non-economic damages (loss of companionship), how settlement value is estimated, state-by-state damage caps and rule differences, statutes of limitations, the difference between a survival action and a wrongful death claim, contingency fees, and the tax treatment of awards — explained for U.S. readers in practical terms.
A 2026 guide to professional liability insurance — errors & omissions (E&O) — for U.S. consultants and professional-service firms: what it covers (negligence, mistakes, missed deadlines, breach of duty), how it differs from general liability, the cost drivers (revenue, industry, limits, claims history), claims-made vs occurrence, retroactive dates and tail coverage, and how much coverage a consultant actually needs.
Nano-X Imaging (NNOX) 2026 stock analysis: cold-cathode Nanox.ARC digital tomosynthesis, pay-per-scan imaging-as-a-service model, Nanox.AI, FDA and deployment execution risk, past short-seller controversy, cash burn, and the traits of a high-volatility no-dividend small cap.
Canadian Solar (CSIQ) 2026 stock analysis: solar module oversupply and price-decline downcycle, e-STORAGE energy-storage growth engine, Recurrent Energy project pipeline and asset recycling, US tariffs, IRA policy, China supply-chain exposure, thin margins, high volatility, and no dividend.
CLIO (KOSDAQ 237880) 2026 stock analysis: Peripera, Goodal, and CLIO brand portfolio, Olive Young H&B channel plus online and global (Japan, US Amazon) expansion, indie-brand competition, cost and marketing structure, and channel-dependence, China-exposure, and trend-sensitivity risks.
Lotte Fine Chemical (KOSPI: 004000) 2026 stock analysis: high-margin food-and-pharma cellulose derivatives (HECELLOSE, AnyCoat) versus commodity chlor-alkali and ammonia cycles, UREX diesel-exhaust fluid, green hydrogen and carbon-free ammonia optionality, net-cash balance sheet, dividend appeal, and Lotte Group risk for foreign investors.